| Dokumentenart: | Artikel | ||||||
|---|---|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Annals of Oncology | ||||||
| Verlag: | ELSEVIER | ||||||
| Ort der Veröffentlichung: | AMSTERDAM | ||||||
| Datum: | 24 August 2021 | ||||||
| Institutionen: | Medizin > Institut für Funktionelle Genomik > Lehrstuhl für Statistische Bioinformatik (Prof. Spang) Informatik und Data Science > Lehrstuhl für Statistische Bioinformatik (Prof. Spang) | ||||||
| Identifikationsnummer: |
| ||||||
| Stichwörter / Keywords: | HIGH-RISK PATIENTS; ELDERLY-PATIENTS; FOLLICULAR LYMPHOMA; OPEN-LABEL; RITUXIMAB; SURVIVAL; TRIAL; PREDICTS; CHEMOTHERAPY; IMPACT; DLBCL; SPARC; tumor microenvironment; pathology; lymphoma; biomarker | ||||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||||
| Status: | Veröffentlicht | ||||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||||
| An der Universität Regensburg entstanden: | Zum Teil | ||||||
| Dokumenten-ID: | 49381 |
Web of ScienceZusammenfassung
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with respect to outcome. Features of the tumor microenvironment (TME) are associated with prognosis when assessed by gene expression profiling. However, it is uncertain whether assessment of the microenvironment can add prognostic information to the most relevant and clinically well-established molecular subgroups when ...
Zusammenfassung
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with respect to outcome. Features of the tumor microenvironment (TME) are associated with prognosis when assessed by gene expression profiling. However, it is uncertain whether assessment of the microenvironment can add prognostic information to the most relevant and clinically well-established molecular subgroups when analyzed by immunohistochemistry (IHC). Patients and methods: We carried out a histopathologic analysis of biomarkers related to TME in a very large cohort (n = 455) of DLBCL treated in prospective trials and correlated with clinicopathologic and molecular data, including chromosomal rearrangements and gene expression profiles for cell-of-origin and TME. Results: The content of PD1+, FoxP3+ and CD8+, as well as vessel density, was not associated with outcome. However, we found a low content of CD68+ macrophages to be associated with inferior progression-free survival (PFS) and overall survival (OS; P = 0.023 and 0.040, respectively) at both univariable and multivariable analyses, adjusted for the factors of the International Prognostic Index (IPI), MYC break and BCL2/MYC and BCL6/MYC double-hit status. The subgroup of PDL1+ macrophages was not associated with survival. Instead, secreted protein acidic and cysteine rich (SPARC)-positive macrophages were identified as the subtype of macrophages most associated with survival. SPARC-positive macrophages and stromal cells directly correlated with favorable PFS and OS (both, P[log rank] <0.001, P[trend] < 0.001). The association of SPARC with prognosis was independent of the factors of the IPI, MYC double-/triple-hit status, BcI2/c-myc double expression, cell-of-origin subtype and a recently published gene expression signature [lymphoma-associated macrophage interaction signature (LAMIS)]. Conclusions: SPARC expression in the TME detected by a single IHC staining with fair-to-good interobserver reproducibility is a powerful prognostic parameter. Thus SPARC expression is a strong candidate for risk assessment in DLBCL in daily practice.
Metadaten zuletzt geändert: 13 Okt 2021 04:19
Altmetric